公开(公告)号：US11098089B2

公开(公告)日：2021-08-24

申请号：US16606958

申请日：2018-04-19

Applicant: Biological E Limited

Inventor： Balamurali Masilamani ,  Rajan Sriraman ,  Mandar Shirish Dixit ,  Deviprasanna Chakka ,  Satyam Naidu Sureddi ,  Ramesh Venkat Matur ,  Narender Dev Mantena ,  Mahima Datla

IPC: C12N1/20 ,  A61K39/05 ,  A61K39/385 ,  C12P21/00 ,  C07K14/34

Abstract: The present invention provides an improved method for the production of CRM197 with high yield using engineered Corynebacterium diphtheria strain having an increased copy number of the CRM197 gene, wherein the method comprises growing the strain in media free of animal-derived components with one or more amino acids.

公开(公告)号：US20230101892A1

公开(公告)日：2023-03-30

申请号：US18074884

申请日：2022-12-05

Applicant: Biological E Limited

Inventor： Ramesh Venkat Matur ,  Rajan Sriraman ,  Deviprasanna Chakka ,  Satyam Naidu Sureddi ,  Rajendar Burki ,  Sreenivasa Rao Ganti ,  Narender Dev Mantena ,  Mahima Datla

IPC: A61K39/09 ,  A61K39/39 ,  A61P31/04

Abstract: The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following: a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.

公开(公告)号：US11547752B2

公开(公告)日：2023-01-10

申请号：US16369933

申请日：2019-03-29

Applicant: BIOLOGICAL E LIMITED

Inventor： Ramesh Venkat Matur ,  Rajan Sriraman ,  Deviprasanna Chakka ,  Satyam Naidu Sureddi ,  Rajendar Burki ,  Sreenivasa Rao Ganti ,  Narender Dev Mantena ,  Mahima Datla

IPC: A61K39/09 ,  A61K39/39 ,  A61K39/385 ,  A61K9/00 ,  A61K39/00

Abstract: The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.

公开(公告)号：US20200277341A1

公开(公告)日：2020-09-03

申请号：US16606958

申请日：2018-04-19

Applicant: Biological E Limited

Inventor： Balamurali Masilamani ,  Rajan Sriraman ,  Mandar Shirish Dixit ,  Deviprasanna Chakka ,  Satyam Naidu Sureddi ,  Ramesh Venkat Matur ,  Narender Dev Mantena ,  Mahima Datla

IPC: C07K14/34 ,  C12N1/20 ,  C12P21/00 ,  A61K39/05 ,  A61K39/385

Abstract: The present invention provides an improved method for the production of CRM197 with high yield using engineered Corynebacterium diphtheria strain having an increased copy number of the CRM197 gene, wherein the method comprises growing the strain in media free of animal-derived components with one or more amino acids.

公开(公告)号：US20190224295A1

公开(公告)日：2019-07-25

申请号：US16369933

申请日：2019-03-29

Applicant: BIOLOGICAL E LIMITED

Inventor： Ramesh Venkat Matur ,  Rajan Sriraman ,  Deviprasanna Chakka ,  Satyam Naidu Sureddi ,  Rajendar Burki ,  Sreenivasa Rao Ganti ,  Narender Dev Mantena ,  Mahima Datla

IPC: A61K39/09 ,  A61K9/00

Abstract: The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.